A Venture Capital firm based in the US typically invests between $3-5M initially and $6M to $10M over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes.
The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Device and Healthcare IT spaces. In the Therapeutics space, the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics, the firm is looking for companies primarily with a lead product in preclinical trials, although they will consider companies with products having recently entered Phase I.
In the Medical Device space, the firm strongly prefers that the company at least has an early prototype of their product and the firm is opportunistic in terms of medical device subsector and is open to all classes of device.
In Healthcare IT, the firm is interested in three specific areas: (1) modernizing operations with innovative delivery models, insurance products and clinical trial automation, (2) technology that drive precision in care personalization/targeted therapy and enhanced disease and care management tools, (3) IT empowering patients and caregivers with health education, price/quality transparency, health surveillance and biometric monitoring for enhanced senior care.
For Healthcare IT investments, the firm looks only at post-revenue companies. For drug and device deals, however, the firm only invests in pre-revenue companies and often works with spinouts directly from universities, though this is not a requirement as the firm is open to all types of early stage companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment